Navigation Links
Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer

HUNTSVILLE, Ala., April 16, 2007 /PRNewswire/ -- Expression Genetics, Inc., announced today the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001. The study, conducted at The University of Alabama at Birmingham and , evaluated the safety, tolerance, preliminary efficacy, and biological activity of the EGEN-001 in 13 patients with advanced recurrent epithelial ovarian cancer. The product, utilizing the Company's proprietary TheraPlas(R) delivery technology, is composed of interleukin-12 (IL-12) gene expression plasmid formulated with a biocompatible delivery polymer and is designed to increase local concentration of IL-12 protein. IL-12 is a potent anti-cancer cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply. EGEN-001 for treatment of ovarian cancer has been granted Orphan Drug Status by the FDA.

The Phase I clinical trial was an open-label dose escalation study involving four dose levels of EGEN-001 administered intraperitoneally by four weekly infusions in chemotherapy-resistant advanced stage recurrent ovarian cancer patients. The treatment was well tolerated with no apparent dose- related trends in clinical laboratory, ECG, or vital sign parameters. General observations included abdominal cramping, mild to moderate peritonitis, nausea, and mild elevation of body temperature. These data demonstrate that this IL-12 gene therapeutic is safe for intraperitoneal administration in ovarian cancer patients.

Several clinical and biological parameters were evaluated as secondary endpoints of this study. Tumor burden of patients was monitored during treatment and results show 31% of patients showed stable disease. To date, the overall median survival is over 12.2 months with 7 out of 13 patients still surviving. There appeared to be some trend with respect to clinical benefit in the patients treated with
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/24/2014)... WASHINGTON , July 24, 2014  The ... Brightree is supporting its mission to help address ... new and exclusive agreement to be the information ... service. As the leading provider of billing and ... brings unmatched HME industry expertise to support this ...
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % to Rs. 1848.46 ... India Business grew by 20.87% to Rs. 3,971.59 Mn ... Rest of World (ROW) Business grew by 20.67% to Rs. 2,113.09 ... 977.26 Mn Latin America Business grew by 33.92% to ... the research-led global integrated pharmaceutical company, today announced its results for ...
(Date:7/24/2014)... -- "North America Orthopedic Braces and Supports Market Outlook ... America Orthopedic Braces and Supports market. The report provides ... units) and average price data (in US dollars), within ... , Ankle Braces and Supports , Spinal ... Supports. Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
Breaking Medicine Technology:Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
... ANGLETON, Texas, June 2, 2011 Benchmark Electronics, Inc. ... manufacturing provider, announced today that a product it helped ... Design Excellence Award and 2011 Edison Award for best ... 3M™ Integrated Cycler, which has won a 2011 Medical ...
... 2, 2011 Craneware, Inc., the market leader ... multi-year agreement today with Kingman Regional Medical Center, ... Recognized as one of the nation,s five star ... will add Craneware InSight Denials® to the range ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 3Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 4
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... a renowned wedding dress manufacturer and retailer, has recently ... . According to the company’s marketing specialist, all these ... prices, up to 59% off. The special offer will ... Most of the casual party dresses provided by iFitDress.com ... for special designs, delicate craftsmanship and affordable rates. Now, ...
(Date:7/24/2014)... [Brown University] The U.S. Preventive Services Task ... for people at high risk for cancer, but ... patients will have positive results on the screening ... testing. Many policymakers have expressed concern that this ... needlessly upset. A new study of National Lung ...
(Date:7/24/2014)... The Traffic and Leads Training Academy ... help users generate traffic and leads has just been ... throughout the internet marketing community. The excitement surrounding the ... Hendricks prompting a comprehensive review of the course. ... marketing will tell you, it can be quite challenging ...
(Date:7/24/2014)... Triangle Park, NC (PRWEB) July 24, 2014 ... elderly, ethnic minorities, and low-income households are disproportionately ... and public food safety net in the United ... International. , Under Section 743 of the Consolidated ... U.S. Department of Agriculture's Food and Nutrition Service ...
Breaking Medicine News(10 mins):Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Traffic And Leads Training Academy - Review Examining Jeff Johnson’s New IM Course Released 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3
... Accompanies Manuscript in March IssueTAMPA, Fla., March 2 ... peginterferon alfa-2a and ribavirin in patients with chronic ... was published in the March issue of ... Gastroenterological Association Institute (AGA Institute). The study showed ...
... 2 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that the Company has amended the maturity ... with Valens U.S. (formerly Laurus Master Funds). , ... to a near-term extension of this facility, originally ...
... 2 Cardiac Science Corporation (Nasdaq: CSCX ... rehabilitation, and informatics products, announced today that it will ... March 12, 2009 after the market close. The Company ... for 4:30 p.m. Eastern Time. During the call, ...
... APA,s Psychologically Healthy Workplace Awards, Ten Honored for ... of the economy can be felt across all ... during tough economic times reap rewards for employer ... (APA) at its Psychologically Healthy Workplace Awards ceremony ...
... uninsured and underinsured is destabilizing state,s health care safety net. Health ... , ... Detroit, Michigan (PRWEB) March 2, 2009 -- ... and destabilizing the state,s health care delivery system. More than one ...
... Drinking one glass of wine a day may lower ... a new study by the Kaiser Permanente Division of Research ... is a precursor to esophageal cancer, the nation,s fastest growing ... the last 30 years. , Barrett,s Esophagus affects 5 ...
Cached Medicine News:Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 2Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 3Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 4Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 2Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 3Health News:Cover The Uninsured Week, March 22 - 28 in Michigan 4Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 2Health News:Drinking wine lowers risk of Barrett's esophagus, precursor to nation's fastest growing cancer 3
... Cool Line catheter is inserted into the ... the superior vena cava. The Cool ... have sterile, temperature-controlled saline flowing within a ... the central circulation. The Cool Line ...
...
... ability of interventional cardiologists and cardiothoracic ... and provides non-interventional cardiologists with a ... of patients who have become refractory ... a noninvasive, atraumatic treatment for coronary ...
Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
Medicine Products: